CD2-HM1N37-100μg / 询价
CD2-HM1N37-100μg x 5 / 询价
CD2-HM1N37-100μg x 10 / 询价
- 客服电话
- 技术支持
FITC-equivalent Human CD20 Protein-Nanodisc
Recombinant FITC-equivalent Human CD20 Protein-Nanodisc is expressed from HEK293 with His tag at the C-terminus.It contains Met1-Pro297 [Accession | P11836-1].
The protein has a predicted MW of 34.3 kDa kDa.
Excitation Wavelength: 490 nm
Emission Wavelength: 520 nm
Less than 1EU per μg by the LAL method.
Supplied as 0.22 μm filtered solution in PBS (pH 7.4). Notice: Not recommended for immunization.
Valid for 12 months from date of receipt when stored at -80°C.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Immobilized Rituximab, hFc Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for FITC-equivalent Human CD20 Nanodisc, His Tag with the EC50 of 14.6ng/ml determined by ELISA (QC Test).
Immobilized FITC-equivalent Human CD20 Nanodisc, His Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Obinutuzumab, hFc Tag with the EC50 of 35.3ng/ml determined by ELISA.
FITC-equivalent Human CD20 Nanodisc, His Tag captured on CM5 Chip via anti-his antibody can bind Rituximab, hFc Tag with an affinity constant of 3.09 nM as determined in SPR assay (Biacore T200).
FITC-equivalent Human CD20 Nanodisc, His Tag captured on CM5 Chip via anti-his antibody can bind Ofatumumab, hFc Tag with an affinity constant of 153.07 nM as determined in SPR assay (Biacore T200).
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
MS4A1; CD20; MS4A-1; B1; Bp35; CD20 receptor; CD20S7; CVID5; LEU-16; Ly-44; MS4A2; S7
(1)Ma D , Mcdevitt M R , Barendswaard E , et al. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies[J]. Leukemia, 2002, 16(1):60-66.
(2)Jager U , Fridrik M , Zeitlinger M , et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response[J]. Haematologica, 2012, 97(9):1431-1438.
